New technology used in the fight against COVID-19 in a Finnish hospital district

medixine-omatays-covid-korona

Medixine’s technology has been introduced in the Pirkanmaa hospital district in the fight against Coronavirus. The tracing team of Pirkanmaa Hospital District uses Medixine’s service to map contacts of infected people and spread of coronavirus.

Until now, the tracing team has personally called corona-infected people and mapped out where patients may have become infected and whether others could have been exposed to the virus. Now, Medixine’s technology has made it possible to speed up and streamline the work by allowing patients to fill in a tracking survey electronically in the OmaTays service.

Seeing the answers to our tracking survey immediately helps us prioritize who we will call. Such cases include, for example, observations of mass exposure or when the infected person is a health or social care professional. Some of the contacts are handled by the infectious disease officer of the patient’s home community.”
Infection doctor, Ville Kaila

If a person’s test result is negative but later has a new suspected infection, the survey will be completed again. In this way, a potential exposure for that period can be traced.

“We are extremely happy to be able to help professionals in their demanding work against the COVID-19 pandemia. With a long history in cooperation with Pirkanmaa hospital District we were able to rapidly deploy the corona specific features that the customer requested”, says Medicine’s CEO Mr. Lasse Rousi.

OmaTays news about the project:
 icon-external-link https://www.tays.fi/fi-FI/Koronaan_sairastuneiden_kontakteja_selvi(107229)

 

Medixine has extensive experience in the treatment and follow-up of diseases with advanced telemedicine solutions. Our solution is designed to provide all the necessary telecare tools in a user-friendly, proven and effective way. With our scalable and configurable solution already in large scale production, Medixine can deliver secure and powerful solutions fast.

For more information please contact Lasse Rousi, CEO Medixine, lasse.rousi@medixine.com